DENTSPLY SIRONA (NASDAQ:XRAY) Stock Gets Price Target Reduction from Mizuho

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price decreased by Mizuho from $14.00 to $12.00 in a research note published on Thursday morning, Marketbeat reports. Mizuho currently has a neutral rating on the medical instruments supplier’s stock.

Several other equities analysts have also commented on XRAY. Barclays upped their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a report on Monday, August 10th. Leerink Partners cut their target price on DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Finally, Piper Sandler decreased their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Friday, October 9th. Three analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $12.77.

DENTSPLY SIRONA Trading Down 0.7%

NASDAQ XRAY opened at $9.43 on Thursday. The firm’s 50-day moving average is $9.87 and its two-hundred day moving average is $10.95. DENTSPLY SIRONA has a 12 month low of $8.32 and a 12 month high of $14.76. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07. The stock has a market capitalization of $1.88 billion, a P/E ratio of -3.43, a PEG ratio of 1.20 and a beta of 0.87.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. The company had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. DENTSPLY SIRONA’s revenue was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts anticipate that DENTSPLY SIRONA will post 1.39 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Nykredit A S acquired a new position in DENTSPLY SIRONA during the 2nd quarter worth approximately $38,000. IFP Advisors Inc increased its position in shares of DENTSPLY SIRONA by 244.4% in the 3rd quarter. IFP Advisors Inc now owns 5,566 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 3,950 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at $51,000. Public Employees Retirement System of Ohio acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at $69,000. Finally, Citizens Financial Group Inc. RI acquired a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at $118,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.